Avricore Health Inc. Files November 2025 6-K Report
Ticker: AVCRF · Form: 6-K · Filed: Dec 10, 2025 · CIK: 1355736
| Field | Detail |
|---|---|
| Company | Avricore Health INC. (AVCRF) |
| Form Type | 6-K |
| Filed Date | Dec 10, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, company-update
Related Tickers: AVRX
TL;DR
Avricore Health (AVRX) filed its Nov 2025 6-K, standard foreign private issuer report.
AI Summary
Avricore Health Inc. filed a Form 6-K on December 10, 2025, for the reporting period ending November 30, 2025. The company, formerly known as Vanc Pharmaceuticals Inc., NUVA Pharmaceuticals Inc., and ALDA Pharmaceuticals Corp., is based in Vancouver, BC. This filing is a report of a foreign private issuer.
Why It Matters
This filing provides routine updates for investors and regulators regarding the company's status as a foreign private issuer. It confirms the reporting period and company details, which is standard for ongoing compliance.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain significant new financial or operational information that would typically increase risk.
Key Players & Entities
- Avricore Health Inc. (company) — Registrant
- Vanc Pharmaceuticals Inc. (company) — Former company name
- NUVA Pharmaceuticals Inc. (company) — Former company name
- ALDA Pharmaceuticals Corp. (company) — Former company name
- December 10, 2025 (date) — Filing date
- November 30, 2025 (date) — Reporting period end date
FAQ
What is the primary purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of November 2025.
What is Avricore Health Inc.'s principal executive office address?
The principal executive office is located at 1120-789 West Pender St, Vancouver, BC, V6C 1H2.
When was Avricore Health Inc. formerly known as Vanc Pharmaceuticals Inc.?
The company was formerly known as Vanc Pharmaceuticals Inc. prior to a name change on September 11, 2014.
Does Avricore Health Inc. file annual reports under Form 20-F or Form 40-F?
Avricore Health Inc. files annual reports under Form 20-F, as indicated by the checkmark in the filing.
What is the SIC code for Avricore Health Inc.?
The Standard Industrial Classification (SIC) code for Avricore Health Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 384 words · 2 min read · ~1 pages · Grade level 17.5 · Accepted 2025-12-10 16:13:00
Filing Documents
- form6-k.htm (6-K) — 19KB
- ex1.htm (EX-1) — 34KB
- ex1_001.jpg (GRAPHIC) — 11KB
- 0001493152-25-027070.txt ( ) — 69KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AVRICORE HEALTH INC. Date: December 10, 2025 By “Kiki Smith” Kiki Smith Chief Financial Officer SEC1815(04-09) Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number